Compare ALLR & AIHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALLR | AIHS |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.6M | 21.8M |
| IPO Year | 2021 | 2017 |
| Metric | ALLR | AIHS |
|---|---|---|
| Price | $1.22 | $1.39 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.75 | N/A |
| AVG Volume (30 Days) | ★ 101.8K | 84.2K |
| Earning Date | 05-15-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $320,000.00 | ★ $1,546,127.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.77 | $0.83 |
| 52 Week High | $2.35 | $8.26 |
| Indicator | ALLR | AIHS |
|---|---|---|
| Relative Strength Index (RSI) | 46.26 | 55.41 |
| Support Level | $1.01 | $1.13 |
| Resistance Level | $1.27 | $1.59 |
| Average True Range (ATR) | 0.08 | 0.17 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 69.51 | 76.25 |
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
Senmiao Technology Ltd is a holding company. Along with its subsidiaries, it is engaged in facilitating automobile transactions and offering related services. The group's business activities include providing car rental services to individual customers with lease term no more than twelve months; leasing and servicing of new energy vehicles; offering services to automobile purchasers throughout the purchase process; providing management and related services to Partner Platforms and other companies; automobile financing; and providing other related supporting services to customers. The majority of the group's revenue is generated from its automobile rental business.